» Articles » PMID: 38602519

Dynamic Evolution of Kidney Function in Patients with STEC-hemolytic Uremic Syndrome Followed for More Than 15 years: Unexpected Changes

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2024 Apr 11
PMID 38602519
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Most studies regarding kidney outcomes in patients with Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome (STEC-HUS) focus on kidney status at last assessment. We aimed to describe patterns of changes in kidney function during follow-up and investigate associations between kidney function at 1st, 5th, and 10th year after onset and long-term kidney outcomes.

Methods: Data of patients with STEC-HUS followed for at least 15 years were analyzed. Kidney function patterns were constructed considering kidney status at 1st, 5th, 10th, and ≥ 15 years and defined as (1) progressive, if patients changed from complete recovery to any chronic kidney disease (CKD) stage or if CKD worsened; (2) improvement, if they shifted from any CKD stage to complete recovery or to a milder stage; and (3) stable, if remained unchanged.

Results: Of 152 patients included, after 1 year of follow-up, 47% had complete recovery, 22% CKD1, and 32% CKD2-5. At last assessment, 46% had complete recovery, 34% CKD1, and 19% CKD2-5. Despite percentages seeming similar, patients differed: 48% were stable, 27% improved, and 25% worsened. Further, 62% of patients with CKD2-4 in the 1st year normalized their glomerular filtration rate (GFR) thereafter. Comparison of kidney function between 1st, 5th, and 10th year to last assessment shows a stable pattern in 48, 59, and 69% respectively.

Conclusions: Changes in kidney function showed a dynamic and complex behavior, with patients moving from one group to another. Consistently, kidney function neither at the 1st, 5th, or 10th year was representative of final outcome. Unexpectedly, two-thirds of patients with CKD2-4 after 1 year achieved normal eGFR later during follow-up.

Citing Articles

Changing Epidemiology and Outcomes of Hemolytic Uremic Syndrome in Children: A Prospective National Cohort Study from the Polish Pediatric HUS Registry and the Polish Registry of Renal Replacement Therapy in Children.

Zagozdzon I, Szczepanska M, Leszczynska B, Jarmuzek W, Miklaszewska M, Tkaczyk M J Clin Med. 2024; 13(21).

PMID: 39518638 PMC: 11546500. DOI: 10.3390/jcm13216499.

References
1.
Spizzirri F, Rahman R, Bibiloni N, Ruscasso J, Amoreo O . Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol. 1997; 11(2):156-60. DOI: 10.1007/s004670050248. View

2.
Siegler R, Milligan M, Burningham T, Christofferson R, Chang S, Jorde L . Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr. 1991; 118(2):195-200. DOI: 10.1016/s0022-3476(05)80482-2. View

3.
Spinale J, Ruebner R, Copelovitch L, Kaplan B . Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol. 2013; 28(11):2097-105. DOI: 10.1007/s00467-012-2383-6. View

4.
Alconcher L, Lucarelli L, Bronfen S, Villarreal F . Kidney sequelae in 281 Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome patients after a median follow-up of 12 years. Pediatr Nephrol. 2023; 39(4):1221-1228. DOI: 10.1007/s00467-023-06183-7. View

5.
Pundziene B, Dobiliene D, Cerkauskiene R, Mitkiene R, Medzeviciene A, Darskuviene E . Long-term follow-up of children with typical hemolytic uremic syndrome. Medicina (Kaunas). 2017; 51(3):146-151. DOI: 10.1016/j.medici.2015.06.004. View